{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:11Z","timestamp":1791006911017,"version":"4.1.0"},"reference-count":60,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/irdr.2026.01026","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:10:00Z","timestamp":1783635000000},"page":"219-231","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies"],"prefix":"10.5582","volume":"15","author":[{"given":"Kuan-Yu","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Stomatology, Taipei City Hospital, Taipei, Taiwan."},{"name":"School of Dentistry and Graduate Institute of Dental Science, College of Oral Medicine, National Defense Medical Center, Taipei, Taiwan."},{"name":"Department of Health and Welfare, University of Taipei, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. Nat Rev Dis Primers. 2016; 2:16080.","DOI":"10.1038\/nrdp.2016.80"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol. 2009; 66:85-91.","DOI":"10.1001\/archneurol.2008.526"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Manwaring N, Jones MM, Wang JJ, Rochtchina E, Howard C, Mitchell P, Sue CM. Population prevalence of the MELAS A3243G mutation. Mitochondrion. 2007; 7:230-233.","DOI":"10.1016\/j.mito.2006.12.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kirino Y, Goto Y, Campos Y, Arenas J, Suzuki T. Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease. Proc Natl Acad Sci U S A. 2005; 102:7127-7132.","DOI":"10.1073\/pnas.0500563102"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015; 116:4-12.","DOI":"10.1016\/j.ymgme.2015.06.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A&gt;G mitochondrial DNA mutation. Arch Neurol. 2006; 63:1701-1706.","DOI":"10.1001\/archneur.63.12.1701"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cox BC, Pearson JY, Mandrekar J, Gavrilova RH. The clinical spectrum of MELAS and associated disorders across ages: A retrospective cohort study. Front Neurol. 2023; 14:1298569.","DOI":"10.3389\/fneur.2023.1298569"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lorenzoni PJ, Werneck LC, Kay CS, Silvado CE, Scola RH. When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? Arq Neuropsiquiatr. 2015; 73:959-967.","DOI":"10.1590\/0004-282X20150154"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chanoine JP, Thompson DM, Lehman A. Diabetes associated with maternally inherited diabetes and deafness (MIDD): From pathogenic variant to phenotype. Diabetes. 2025; 74:153-163.","DOI":"10.2337\/db24-0515"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Deschauer M, M\u00fcller T, Wieser T, Schulte-Mattler W, Kornhuber M, Zierz S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch Neurol. 2001; 58:1885-1888.","DOI":"10.1001\/archneur.58.11.1885"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fayssoil A. Heart diseases i n mitochondrial encephalomyopathy, lactic acidosis, and stroke syndrome. Congest Heart Fail. 2009; 15:284-287.","DOI":"10.1111\/j.1751-7133.2009.00108.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Daruich A, Matet A, Borruat FX. Macular dystrophy associated with the mitochondrial DNA A3243G mutation: Pericentral pigment deposits or atrophy? Report of two cases and review of the literature. BMC Ophthalmol. 2014; 14:77.","DOI":"10.1186\/1471-2415-14-77"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009; 11:414-430.","DOI":"10.1007\/s11940-009-0046-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Suzuki T, Suzuki T, Wada T, Saigo K, Watanabe K. Taurine as a constituent of mitochondrial tRNAs: New insights into the functions of taurine and human mitochondrial diseases. EMBO J. 2002; 21:6581-6589.","DOI":"10.1093\/emboj\/cdf656"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, Ishii M, Matsuishi T. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology. 2006; 66:1766-1769.","DOI":"10.1212\/01.wnl.0000220197.36849.1e"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Smeitink J, van Es J, Bosman B, <i>et al.<\/i> Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A&gt;G mutation. Brain. 2025; 148:896-907.","DOI":"10.1093\/brain\/awae277"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Steele H, Gomez-Duran A, Pyle A, <i>et al.<\/i> Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol Med. 2020; 12:e11589.","DOI":"10.15252\/emmm.201911589"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yahata N, Goto YI, Hata R. Optimization of mtDNA-targeted platinum TALENs for bi-directionally modifying heteroplasmy levels in patient-derived m.3243A&gt;G-iPSCs. Mol Ther Nucleic Acids. 2025; 36:102521.","DOI":"10.1016\/j.omtn.2025.102521"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583:631-637.","DOI":"10.1038\/s41586-020-2477-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Asano K, Suzuki T, Saito A, <i>et al.<\/i> Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease. Nucleic Acids Res. 2018; 46:1565-1583.","DOI":"10.1093\/nar\/gky068"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kirino Y, Yasukawa T, Ohta S, Akira S, Ishihara K, Watanabe K, Suzuki T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc Natl Acad Sci U S A. 2004; 101:15070-15075.","DOI":"10.1073\/pnas.0405173101"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rikimaru M, Ohsawa Y, Wolf AM, Nishimaki K, Ichimiya H, Kamimura N, Nishimatsu S, Ohta S, Sunada Y. Taurine ameliorates impaired mitochondrial function and prevents stroke-like episodes in patients with MELAS. Intern Med. 2012; 51:3351-3357.","DOI":"10.2169\/internalmedicine.51.7529"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: A multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2019; 90:529-536.","DOI":"10.1136\/jnnp-2018-317964"},{"key":"24","unstructured":"24. Pharmaceuticals and Medical Devices Agency (PMDA). Pharmaceuticals and Medical Devices Agency (PMDA). List of Newly Approved Drugs, FY2018 (April 2018\u2013March 2019). Tokyo: PMDA; 2019. No. 22. Taurine Powder 98% (Taisho Pharmaceutical Co., Ltd.); approved February 21, 2019; indication: suppression of stroke-like episodes in MELAS syndrome; designated as an orphan drug. <i>https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0030.html<\/i> (accessed June 30, 2026)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci. 2010; 1201:104-110.","DOI":"10.1111\/j.1749-6632.2010.05624.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ikawa M, Okazawa H, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, Kuriyama M, Yoneda M. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009; 9:144-148.","DOI":"10.1016\/j.mito.2009.01.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Koenig MK, Emrick L, Karaa A, Korson M, Scaglia F, Parikh S, Goldstein A. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. JAMA Neurol. 2016; 73:591-594.","DOI":"10.1001\/jamaneurol.2015.5072"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 2018; 265:2861-2874.","DOI":"10.1007\/s00415-018-9057-7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Parikh S, Goldstein A, Koenig MK, <i>et al<\/i>. Diagnosis and management of mitochondrial disease: A consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015; 17:689-701.","DOI":"10.1038\/gim.2014.177"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. E l - H a t t a b AW, A l m a n n a i M , S c a g l i a F. Arginine and citrulline for treatment of MELAS syndrome. J Inborn Errors Metab Screen. 2017; 5:10.1177\/2326409817697399.","DOI":"10.1177\/2326409817697399"},{"key":"31","unstructured":"31. ClinicalTrials.gov. Phase-1, dose finding and safety study on L- citrulline treatment of nitric oxide deficiency in MELAS <i>https:\/\/clinicaltrials.gov\/study\/NCT03952234<\/i> (accessed June 30, 2026)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Janssen MCH, Koene S, de Laat P, Hemelaar P, Pickkers P, Spaans E, Beukema R, Beyrath J, Groothuis J, Verhaak C, Smeitink J. The KHENERGY study: Safety and efficacy of KH176 in mitochondrial m.3243A&gt;G spectrum disorders. Clin Pharmacol Ther. 2019; 105:101-111.","DOI":"10.1002\/cpt.1197"},{"key":"33","unstructured":"33. KHONDRION. Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders. <i>https:\/\/www.khondrion.com\/news\/khondrion-announces-sonlicromanol-phase-iib-progress-supporting-phase-iii-development-in-melas-spectrum-disorders<\/i> (accessed June 30, 2026)."},{"key":"34","unstructured":"34. KHONDRION. Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease. <i>https:\/\/www.khondrion.com\/news\/khondrion-announces-publication-in-brain-of-integrated-phase-2b-program-demonstrating-disease-modifying-potential-of-sonlicromanol-in-primary-mitochondrial-disease<\/i> (accessed June 30, 2026)."},{"key":"35","unstructured":"35. ClinicalTrials.gov. A phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A&gt;G variant. <i>https:\/\/clinicaltrials.gov\/study\/NCT06451757<\/i> (accessed June 30, 2026)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Seo KS, Kim JH, Min KN, Moon JA, Roh TC, Lee MJ, Lee KW, Min JE, Lee YM. KL1333, a novel NAD<sup>+<\/sup> modulator, improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. Front Neurol. 2018; 9:552.","DOI":"10.3389\/fneur.2018.00552"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Pizzamiglio C, Stefanetti RJ, McFarland R, Thomas N, Ransley G, Hugerth M, Gr\u00f6nberg A, Serrano SS, Elm\u00e9r E, Hanna MG, Hansson MJ, Gorman GS, Pitceathly RDS. Optimizing rare disorder trials: A phase 1a\/1b randomized study of KL1333 in adults with mitochondrial disease. Brain. 2025; 148:39-46.","DOI":"10.1093\/brain\/awae308"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Evgenov OV, Pacher P, Schmidt PM, Hask\u00f3 G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat Rev Drug Discov. 2006; 5:755-768.","DOI":"10.1038\/nrd2038"},{"key":"39","unstructured":"39. ClinicalTrials.gov. Phase 2b randomized, double-blind, placebo-controlled crossover study evaluating the efficacy and safety of zagociguat in participants with MELAS (PRIZM). <i>https:\/\/clinicaltrials.gov\/study\/NCT06402123<\/i> (accessed June 30, 2026)."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Guha S, Konkwo C, Lavorato M, Mathew ND, Peng M, Ostrovsky J, Kwon YJ, Polyak E, Lightfoot R, Seiler C, Xiao R, Bennett M, Zhang Z, Nakamaru-Ogiso E, Falk MJ. Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease. Hum Mol Genet. 2019; 28:1837-1852.","DOI":"10.1093\/hmg\/ddz023"},{"key":"41","unstructured":"41. ClinicalTrials.gov. A multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of oral TTI-0102 for treatment of patients with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). <i>https:\/\/clinicaltrials.gov\/study\/NCT06644534<\/i> (accessed June 30, 2026)."},{"key":"42","unstructured":"42. ClinicalTrials.gov. A phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A&gt;G variant. <i>https:\/\/clinicaltrials.gov\/study\/NCT06451757<\/i> (accessed June 30, 2026)."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Fr\u00e4nzel B, Tomaschewski J, Aladini F, Becker C, Wolters D, Steegborn C. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One. 2012; 7:e49761.","DOI":"10.1371\/journal.pone.0049761"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med. 2014; 6:458-466.","DOI":"10.1002\/emmm.201303672"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Joore IP, Shehata S, Muffels I, <i>et al.<\/i> Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoS Biol. 2025; 23:e3003207.","DOI":"10.1371\/journal.pbio.3003207"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Tang J, Du K. Mitochondrial base editing: from principle, optimization to application. Cell Biosci. 2025; 15:9.","DOI":"10.1186\/s13578-025-01351-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Noohi F, Ravitsky V, Knoppers BM, Joly Y. Mitochondrial replacement therapy: In whose interests? J Law Med Ethics. 2022; 5:597-602.","DOI":"10.1017\/jme.2022.98"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Wolf DP, Mitalipov N, Mitalipov S. Mitochondrial replacement therapy in reproductive medicine. Trends Mol Med. 2015; 21:68-76.","DOI":"10.1016\/j.molmed.2014.12.001"},{"key":"49","unstructured":"49. Human Fertilisation &amp; Embryology Authority. HFEA comments on the news that eight babies have been born after mitochondrial donation treatment. <i>https:\/\/www.hfea.gov.uk\/about-us\/news-and-press-releases\/2025\/hfea-comments-on-the-news-that-eight-babies-have-been-born-after-mitochondrial-donation-treatment<\/i> (accessed June 30, 2026)."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Hyslop LA, Blakeley P, Craven L, <i>et al.<\/i> Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016; 534:383-386.","DOI":"10.1038\/nature18303"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Rai PK, Craven L, Hoogewijs K, Russell OM, Lightowlers RN. Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome. Essays Biochem. 2018; 62:455-465.","DOI":"10.1042\/EBC20170113"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Viering D, Schlingmann KP, Hureaux M, <i>et al.<\/i> Gitelman-like syndrome caused by pathogenic variants in mtDNA. J Am Soc Nephrol. 2022; 33:305-325.","DOI":"10.1681\/ASN.2021050596"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Shoop WK, Lape J, Trum M, Powell A, Sevigny E, Mischler A, Bacman SR, Fontanesi F, Smith J, Jantz D, Gorsuch CL, Moraes CT. Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease. Nat Metab. 2023; 5:2169-2183.","DOI":"10.1038\/s42255-023-00932-6"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Russell OM, Gorman GS, Lightowlers RN, Turnbull DM. Mitochondrial Diseases: Hope for the Future. Cell. 2020; 181:168-188.","DOI":"10.1016\/j.cell.2020.02.051"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. Phenotypic heterogeneity in m.3243A&gt;G mitochondrial disease: The role of nuclear factors. Ann Clin Transl Neurol. 2018; 5:333-345.","DOI":"10.1002\/acn3.532"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T, Ito M, Tanaka M, Saiki R, Koga Y. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015; 78:814-823.","DOI":"10.1002\/ana.24506"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018; 391:2560-2574.","DOI":"10.1016\/S0140-6736(18)30727-X"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A&gt;G mitochondrial disease. EMBO Mol Med. 2018; 10:e8262.","DOI":"10.15252\/emmm.201708262"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Wei Y, Li Z, Xu K, Feng H, Xie L, Li D, Zuo Z, Zhang M, Xu C, Yang H, Zuo E. Mitochondrial base editor DdCBE causes substantial DNA off-target editing in nuclear genome of embryos. Cell Discov. 2022; 8:27.","DOI":"10.1038\/s41421-022-00391-5"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J. Therapies for Mitochondrial Disease: Past, Present, and Future. J Inherit Metab Dis. 2025; 48:e70065.","DOI":"10.1002\/jimd.70065"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01026\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:30Z","timestamp":1791005730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01026\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2026.01026","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01026"}}